EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant Achromobacter xylosoxidans

Bhavatharini Arun iD, Rajnikant Sharma, Quentin Vallé, Ngoc Minh Bui, Nicholas Furtado, María Soledad Ramirez iD, Gauri Rao iD

Antimicrobial Agents and Chemotherapy · 04.03.2026 · 70 (3)

DOI: 10.1128/aac.01263-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.03.2026. Verfasst von Bhavatharini Arun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, C…. Hauptthemen laut MEDLINE: Ceftazidime, Cephalosporins, Azabicyclo Compounds, Achromobacter denitrificans. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, U.S. Public Health Service.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achromobacter xylosoxidans harbors robust intrinsic and acquired resistance mechanisms and is responsible for severe nosocomial infections in high-risk individuals. Here, we investigated the effectiveness of β-lactam antibiotic combinations against three sequentially collected A. xylosoxidans isolates from a pediatric patient with chronic myeloid leukemia, which were previously genotyped and sequenced to assess and characterize the evolution of resistance. The time course killing activity from in vitro static concentration time-kill (SCTK) assays and genomics of these longitudinally collected isolates guided the development of an in silico mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model. As previously described, the sequentially collected A. xylosoxidans isolates developed resistance to meropenem and ceftazidime/avibactam during treatment, along with reduced susceptibility to cefiderocol, driven by the acquisition of β-lactamase genes, point mutations, and increased β-lactamase expression. Building on these findings, SCTK assays showed that the combination of ceftazidime/avibactam and cefiderocol achieved ≥2-log reductions in bacterial colony-forming units. The PK/PD model included two bacterial subpopulations, one resistant to ceftazidime but susceptible to cefiderocol and another resistant to both. Avibactam’s mechanistic synergy restored ceftazidime activity. However, the acquisition of resistance genes and mutations led to a 14-fold and 1.5-fold reduction in susceptibility to ceftazidime/avibactam and cefiderocol, respectively. Simulations with the developed model at clinical exposures revealed that this combination had bactericidal activity, and the infusion duration was a critical driver of efficacy. These findings underscore the therapeutic promise of combining ceftazidime/avibactam with cefiderocol for managing complex A. xylosoxidans bacteremia and highlight the potential of integrated mechanism-based modeling to guide treatment strategies in resistant infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeCephalosporinsAzabicyclo CompoundsAchromobacter denitrificansAnti-Bacterial AgentsCarbapenemsCefiderocolMicrobial Sensitivity TestsDrug CombinationsHumansbeta-LactamasesGenomicsThird Generation CephalosporinsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Achromobacter xylosoxidansantimicrobial resistancebacterial genomicsimmunocompromised hostsmathematical modelβ-lactams

Substanzen

CefiderocolCeftazidimeCephalosporinsAzabicyclo CompoundsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationDrug Combinationsbeta-LactamasesCarbapenemsThird Generation Cephalosporins

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
  • Department of Biological Science, Center for Applied Biotechnology Studies, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, California, USA.

ORCID-Profile: Bhavatharini Arun, María Soledad Ramirez, Gauri Rao

Förderung

  • National Institute of Allergy and Infectious Diseases
  • U.S. Public Health Service

Zitieren

APA

Arun, B., Sharma, R., Vallé, Q., Bui, N. M., Furtado, N., Ramirez, M. S., & Rao, G. (2026). A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant Achromobacter xylosoxidans. Antimicrobial Agents and Chemotherapy, 70(3). https://doi.org/10.1128/aac.01263-25

Vancouver

Arun B, Sharma R, Vallé Q, Bui NM, Furtado N, Ramirez MS, et al. A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant Achromobacter xylosoxidans. Antimicrobial Agents and Chemotherapy. 2026;70(3). doi:10.1128/aac.01263-25

BibTeX
@article{Arun2026,
  author = {Arun, Bhavatharini and Sharma, Rajnikant and Vallé, Quentin and Bui, Ngoc Minh and Furtado, Nicholas and Ramirez, María Soledad and Rao, Gauri},
  title = {A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant Achromobacter xylosoxidans},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {3},
  doi = {10.1128/aac.01263-25}
}
Kostenlos starten →